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Abstract
Systemic capillary leak syndrome (SCLS; Clarkson disease) is a rare orphan disor‐
der characterized by transient yet recurrent episodes of hypotension and periph‐
eral oedema due to diffuse vascular leakage of fluids and proteins into soft tissues.
Humoral mediators, cellular responses and genetic features accounting for the clini‐
cal phenotype of SCLS are virtually unknown. Here, we searched for factors altered
in acute SCLS plasma relative to matched convalescent samples using multiplexed
aptamer‐based proteomic screening. Relative amounts of 612 proteins were changed
greater than twofold and 81 proteins were changed at least threefold. Among the
most enriched proteins in acute SCLS plasma were neutrophil granule components in‐
cluding bactericidal permeability inducing protein, myeloperoxidase and matrix met‐
alloproteinase 8. Neutrophils isolated from blood of subjects with SCLS or healthy
controls responded similarly to routine pro‐inflammatory mediators. However, acute
SCLS sera activated neutrophils relative to remission sera. Activated neutrophil su‐
pernatants increased permeability of endothelial cells from both controls and SCLS
subjects equivalently. Our results suggest systemic neutrophil degranulation during
SCLS acute flares, which may contribute to the clinical manifestations of acute vas‐
cular leak.
KEYWORDS

endothelial cells, neutrophils, proteomics, vascular leak

1 | I NTRO D U C TI O N

haematocrit resulting from hemoconcentration and hypoalbumin‐
emia due to leakage from the intravascular space.1 Patients are fre‐

Systemic capillary leak syndrome (SCLS) is an extremely rare and po‐

quently misdiagnosed initially with other conditions such as sepsis

tentially fatal disorder of unknown aetiology. SCLS is characterized

and treated with aggressive intravenous fluid resuscitation. Such

by recurrent, spontaneous attacks of hypovolemic shock and ana‐

therapy induces massive “third spacing” of fluids and solutes into pe‐

sarca due to sudden and massive leakage of intravascular fluids and

ripheral tissues and development of compartment syndromes, which

proteins into peripheral tissues. Termed “Clarkson disease” in 1960

may require fasciotomies. There are no specific treatments for acute

for its discoverer, SCLS is diagnosed based on a unique constella‐

flares of SCLS beyond haemodynamic stabilization, nor is there cu‐

tion of signs and symptoms including severe hypotension, elevated

rative therapy.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
© 2019 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
J Cell Mol Med. 2019;23:5119–5127.
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Specific aetiological factors and pathways contributing the pro‐

(fMLP) were obtained from Sigma‐Aldrich. Human recombinant

found vascular barrier breakdown characteristic of acute SCLS flares

VEGFA‐165 and TNFα were from PeproTech. Antibodies anti‐human

are unknown. Although more than 80% of SCLS patients have a

CD11b/BV786, CD16/APC and CD62L/PE were from Biolegend.

monoclonal gammopathy of unknown significance, there is no direct
or indirect evidence that the monoclonal IgG has any role in disease
pathogenesis.2 In our studies of more than 65 patients with a confirmed

2.3 | SOMAscan and ELISA

diagnosis of SCLS, we found that several inflammatory cytokines (eg

Nine pairs of EDTA‐plasma samples obtained at or near the onset of

TNFα, CCL2, CXCL10) and mediators of vascular permeability (VEGF,

an acute SCLS crisis and from the same patient during a convalescent

Angpt‐2) were significantly elevated in sera from patients during acute

interval were analysed using the SOMAscan Assay Kit for human

episodes compared to convalescent intervals.

2,3

Treatment of normal

plasma 1.3k V3.2 (SomaLogic, Inc, cat.#900‐00011) according to the

vascular endothelial cells (ECs) with acute but not remission sera from

standard protocol for EDTA plasma from the manufacturer's and as

these patients disrupted vascular integrity through mechanisms in‐

described previously.8 Five pooled human plasma controls and one

cluding internalization of VE‐cadherin and actin stress fibre formation.

buffer control were run on the same plate with the test samples for

In order to broaden our search for mediators unique to SCLS and/

calibration and normalization. Median normalization and calibra‐

or uncover a signature of humoral factors characteristic of acute at‐

tion of the data were performed according to the standard quality

tacks, we used the slow‐off rate modified aptamer (SOMA)scan plat‐

control protocols at SomaLogic. All samples passed the established

form, an aptamer‐based highly multiplexed proteomic assay capable

quality control criteria. SOMAscan data were analysed using Partek

of detecting more than 1300 protein analytes simultaneously across

Genomics Suite and statistical significance determined using two‐

the whole dynamic range from only a small volume of plasma with

way ANOVA. Proteins enriched in acute vs remission plasma at least

high sensitivity and specificity.4 The SOMAscan approach uncovered

threefold (P < 0.01) were used to generate the Heatmap. Functional

more than 600 proteins, whose relative amounts were increased more

enrichment was determined using Ingenuity Pathway Analysis

than twofold in acute plasma relative to matched baseline plasma

software (Qiagen) using Fisher's Exact with FDR multiple test cor‐

from the same patients. Most notably, several neutrophil granule

rection. ELISAs for elastase, myeloperoxidase (MPO), α‐defensin,

proteins were profoundly elevated in acute SCLS plasma. Acute but

lactoferrin and MMP‐9 were performed according to the manufac‐

not remission sera from SCLS patients activated neutrophils, and su‐

turer's instructions (Cayman Chemical for MPO; R&D Systems for

pernatants from activated neutrophils induced hyperpermeability of

the remainder).

ECs. These results suggest that activated and/or degranulated neu‐
trophils contribute to the pathogenesis of acute SCLS.

2 | M ATE R I A L S A N D M E TH O DS
2.1 | Subjects

2.4 | Neutrophil isolation
Neutrophils were isolated from whole blood using Hypaque Ficoll
separation. Briefly, 1:1 PBS diluted blood was added onto the top
of Ficoll (lymphocyte separation medium, MP Biomedicals), centri‐
fuged at 800x g at room temperature for 20 minutes with the brake

Patients were diagnosed with SCLS according to established criteria,

off. Neutrophils were retrieved from the bottom layer containing

specifically a history of one or more transient episodes of hypotension,

RBCs. After RBC lysis using ACK lysing buffer, cell pellets were

elevated haematocrit and hypoalbuminemia.5,6 Patients were seen at

washed twice in PBS. Neutrophil purity was routinely ~95% based

the Clinical Center of the National Institutes of Health. Written in‐

on surface marker expression (CD16+, CD3−/CD19−) as determined

formed consent was obtained from each patient and the study protocol

by flow cytometry.

(I‐0184) conformed to the ethical guidelines of the 2008 Declaration
of Helsinki, having been approved by the Institutional Review Board of
the National Institute of Allergy and Infectious Diseases of NIH. EDTA

2.5 | Neutrophil activation/degranulation

plasma and sera were collected and stored from both remission and ac‐

For analysis of neutrophil activation, freshly isolated neutrophils were

tive disease intervals where available. Neutrophils were available only

incubated with buffer or stimuli in culture medium at 37°C for the in‐

from asymptomatic patients. Anonymized age‐, sex‐ and race‐matched

dicated time periods, followed by termination of the reaction by ad‐

blood from healthy volunteers were obtained from the NIH Blood

dition of ice‐cold PBS. Cells were then stained with Live/Dead violet

Bank for neutrophil isolation and used as controls.

(ThermoFisher), washed once and stained with anti‐human CD11b/
BV785, CD16/APC and CD62L/PE. The samples were then analysed

2.2 | Cells and reagents
Human microvascular endothelial cells (HMVECs) and the culture me‐

using an LSRII flow cytometer and the data processed using FlowJo
software (BD BioSciences). MPO levels were determined by ELISA
(Cayman Chemical). Briefly, purified neutrophils were incubated with

dium EGM2 were purchased from Lonza. Blood outgrowth endothelial

fMLP (100 nmol/L) for 15 minutes in complete RPMI at 37°C in the

cells (BOECs) were generated and cultured as described previously.7

presence of cytochalasin B (10 mol/L). Supernatants were collected

Lipopolysaccharide (LPS), cytochalasin B and N‐formyl‐Met‐Leu‐Phe

and analysed by ELISA according to the manufacturer's instructions.

|
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To more fully probe the SCLS proteome, we performed SOMAscan

2.6 | Endothelial permeability measurements

profiling of 1305 proteins in nine matched plasma samples obtained by

An electric cell‐substrate impedance sensing (ECIS) assay was used

venipuncture during acute or convalescent intervals. The characteris‐

to assess endothelial barrier function. Electrical resistance was

tics of these patients are described in Table 1. This assay identified 612

measured across endothelial monolayers at 4,000 Hz using the ECIS

proteins, whose relative amounts were changed at least twofold in epi‐

2

Zθ apparatus (Applied BioPhysics) as described previously. Briefly,

sodic plasma relative to baseline (P < 0.05) (full list in Table S1), and all

ECs were serum starved in endothelial basal medium (EBM2, Lonza)

but three of them were increased. Eighty‐one proteins were increased

plus 0.2% BSA for 5 hours followed by addition of test reagents.

at least threefold in episodic plasma (P < 0.001) (Figure 1A). With one

Resistance was recorded over a period of 20 hours. Each condition

exception, the protein profile of episodic and baseline samples clustered

was measured in duplicate in a single experiment and averaged.

with one another. Consistent with previous studies of our entire SCLS

Absolute resistance values were normalized by subtracting the re‐

cohort, several cytokines and vascular permeability mediators including

sistance at time zero (pre‐treatment); the maximal change in resist‐

CCL2, CXCL10, IL‐12, IL‐1β, TNFα, adrenomedullin, Angpt‐2 and VEGFA

ance was calculated as percentage change over time zero.

were significantly elevated in episodic plasma compared to remission
plasma (Table S2).2,3,10 We also discovered enrichment of several pro‐
teins not previously associated with SCLS including surfactant protein

2.7 | Statistical analysis

D S(P‐D), capping actin protein (CAPG), chymase, allograft inflammatory

ELISA and flow cytometric data were analysed with GraphPad Prism

factor (AIF1), the TNFα superfamily member LIGHT and the stressorin

7 software package. Data were analysed by two‐way ANOVA with

IL‐16 (Table 2). We analysed functional enrichment using Ingenuity

multiple corrections testing, and non‐parametric tests were used for

pathway analysis. In the category of “Disease & Biological Function”,

flow data analysis (Mann‐Whitney test for analysis of two groups;

“Inflammatory response” was the statistically most significant category

Kruskal‐Wallis for analysis of multiple groups). P < 0.05 were con‐

(P = 10−15) (Figure 1B); “Upstream Regulators” enriched in acute SCLS

sidered significant.

samples included several pro‐inflammatory mediators such as LPS,
IL‐1β and TNFα (all P < 10−6) (Figure 1C). Finally, the top “Canonical
Pathways” implicated in acute SCLS were IL‐8 and glucocorticoid signal‐

3 | R E S U LT S

ling (P = 10−6) (Figure 1D).

3.1 | Proteomic profile of acute SCLS plasma

3.2 | Neutrophil activation signature in SCLS
disease flares

Although the clinical symptoms of acute SCLS crises, including hemo‐
dynamic collapse and anasarca, are quite dramatic, patients are typically
asymptomatic in between episodes. Although SCLS flares may occur in

Among the proteins that were increased the most in acute SCLS

the absence of obvious triggers, recent survey studies suggest that in‐

plasma were neutrophil granule components bactericidal perme‐

fections (typically upper respiratory) precede SCLS attacks in 35%‐50%

ability increasing protein (BPI) (19.5‐fold), matrix metalloproteinase

of adult patients.1,9 These findings suggest that infection‐related inflam‐

8 (MMP8, 7.9‐fold) and MMP9 (4.5‐fold) (Table 3). As noted above

matory mediators may induce vascular leakage in some patients. Indeed,

functionally enriched pathways in acute samples included signal‐

in limited prior screening of acute SCLS sera, we found elevated levels of

ling involving IL‐8, a well‐known neutrophil chemoattractant, and

pro‐inflammatory mediators including TNFα, CXCL10, CCL2 and IL‐8.2,3

LPS, which also activates neutrophils.11 Given these findings, we

TA B L E 1
patients

Characteristics of SCLS
Sample #

Sex

Age at
diagnosis

#Episodes

Complications

Current
treatment

1

M

63

>10

None

IVIG

2

F

40

4

CS, neuropathy

IVIG

3

M

48

>20

CS, neuropathy,
thrombosis, GI infarct

IVIG

4

M

48

2

None

IVIG

5

M

46

>10

None

IVIG

6

M

43

11

CS

IVIG

7

M

68

>10

CS

IVIG

8

F

48

2 (+chronic)

Diarrhoea, vomiting,
wasting

None
(deceased)

9

F

37

2

Cardiac tamponade

IVIG

Abbreviation: CS, compartment syndrome; SCLS, systemic capillary leak syndrome
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A

B

C

D

F I G U R E 1 Proteomic profiling of systemic capillary leak syndrome (SCLS) plasma. Nine pairs of matched acute‐remission plasma from
SCLS patients were analysed using SOMAscan. (A), Heatmap representation of relative protein amounts. (B‐D), Disease associations
determined by Ingenuity pathway analysis and represented by P‐values (Fisher's exact test)

Protein

P‐value

Fold change (Epi/
Bas)

Functional annotation
(Ref)

Surfactant protein D
(SP‐D)

0.003019

13.4

Immunomodulatory (22)

Capping actin protein
(CAPG)

0.001301

6.8

Gelsolin‐related (actin
binding protein); inflam‐
mation (23)

Chymase

0.000384

6.56

Mast cell‐derived (24)

Allograft inflammatory
factor 1

0.000172

4.36

Actin‐bindin protein; pro‐
inflammatory (25)

LIGHT

0.001306

3.99

TNFα superfamily (26)

IL‐16

0.000697

3.05

Stressorin (27)

TA B L E 2 Novel systemic capillary leak
syndrome‐associated proteins

|
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hypothesized that neutrophil degranulation and activation may

fMLP stimulation of neutrophils from SCLS subjects and healthy

contribute to SCLS flares. To confirm the presence of systemic neu‐

controls were indistinguishable from one another (Figure 3A). We

trophil degranulation in SCLS, we measured levels of granule compo‐

also assessed neutrophil activation by quantifying surface marker

nents in the same plasma samples used for SOMAscan screening by

expression using flow cytometry. Activated neutrophils upregu‐

quantitative ELISA. Contents of primary granules including elastase,

late CD11b while shedding other membrane‐associated proteins

MPO and α‐defensin, secondary granules (lactoferrin) and tertiary

including CD62L (L‐selectin) and CD16. Baseline expression of nu‐

granules (MMP‐9) were significantly increased in episodic SCLS

merous surface markers was comparable in untouched neutrophils

plasma compared to baseline in all patients (Figure 2A‐E), confirming

from whole blood of SCLS patients and controls as assessed by flow

the SOMAscan‐derived data. Although total neutrophil counts were

cytometry, including granulocyte activation markers 31D8, CD63

not available from the date the acute plasma were drawn, absolute

and CD62L, β2‐integrins and Fc receptors (Figure S2). Likewise,

neutrophilia is not a consistent feature of acute SCLS attacks in our

stimulation of purified neutrophils with several proinflammatory

cohort as a whole although total white blood cell counts may be el‐

mediators including fMLP, TNFα and LPS induced a comparable

evated due to infection and/or hemoconcentration. Indeed, protein

pattern of activation marker expression in neutrophils isolated

extravasation and reduced blood volume may confound interpreta‐

from peripheral blood of healthy donors and SCLS subjects dur‐

tion of plasma protein quantities during an SCLS flare. To evaluate

ing disease‐free intervals (Figure 3B‐D). These results indicate that

the contribution of such factors, we normalized raw SOMAScan val‐

neutrophils from SCLS subjects retain the capacity to degranulate

ues for (MPO, molecular weight 150 kDa) by those for proteins of

and release reactive oxygen species (ROS) in response to pro‐in‐

comparable size, whose relative values were unchanged in matched

flammatory stimuli.

acute and remission samples. MPO corrected for either NrCAM
(molecular weight [mw] 140 kDa) or MET (mw 145 kDa) values were
similar to uncorrected values (Figure S1). Thus, we conclude that

3.4 | Acute SCLS sera induce neutrophil activation

hemoconcentration alone is unlikely to account for the increased

A subpopulation of highly activated neutrophils (CD62LdimCD16bright)

MPO in acute SCLS plasma relative to convalescence. Instead, our

is recruited to the circulation from bone marrow in response to acute

findings suggested that widespread neutrophil degranulation occurs

systemic inflammation associated with sepsis and acute trauma,

in circulation during SCLS crises.

among others.12,13 Given the link between SCLS episodes and in‐
fection, and the presence of pro‐inflammatory cytokines in acute

3.3 | Intrinsic neutrophil function in SCLS

SCLS sera, we hypothesized that SCLS sera and/or plasma activate
neutrophils. To investigate this, we analysed surface marker expres‐

We next determined whether neutrophils from SCLS patients are

sion on purified neutrophils from healthy donors incubated with

intrinsically hyper‐responsive to inflammatory stimuli, which could

various sera by flow cytometry, as the availability of plasma was

account for the increased granule components in acute plasma. We

limited. Treatment of neutrophils with acute SCLS sera significantly

first measured neutrophil oxidative burst using a dihydrorhodamine

increased the activated (CD16bright/CD62Ldim) subpopulation, with

assay. In response to phorbol myristate acetate stimulation, neu‐

a concomitant decrease in the CD16bright/CD62Lbright (quiescent)

trophils from SCLS subjects yielded an average stimulation index

subset, compared to cells treated with matched remission sera.

of 187.7 ± 2.97, well within the normal range of the testing clinical

(Figure 4A‐D). This result suggests that SCLS serum components

laboratory ([115‐291], n = 3), indicating that the neutrophil oxida‐

constrained to acute disease flares activate neutrophils, which in

tive burst is intact in SCLS. We next measured degranulation by

turn could account for the increase in granule components in acute

quantifying MPO secretion. Amounts of MPO released following

SCLS plasma relative to that from asymptomatic individuals.

TA B L E 3 Neutrophil granule‐
associated proteins in acute systemic
capillary leak syndrome sera

Protein

p‐value

Fold change
(Epi/Bas)

Granules

Bactericidal permeability
increasing protein (BPI)

1.65E‐05

19.52

Azurophilic/primary

Myeloperoxidase (MPO)

0.0009012

3.07

Azurophilic/primary

Cathepsin G

0.0011997

2.80

Azurophilic/primary

Matrix Metalloproteinase 8
(MMP8)

0.0190632

7.93

Specific/secondary

Gelatinase (MMP9)

0.0004257

4.54

Tertiary

MMP1

0.0023533

2.62

Tertiary

MMP13

0.0057115

1.66

Tertiary

Significantly enriched neutrophil‐associated proteins identified by SOMAscan are listed in the
table along with their granule locations.
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F I G U R E 2 Levels of neutrophil
granule constituents in systemic capillary
leak syndrome plasma. (A‐E), Levels
of the indicated neutrophil granule
components were determined in matched
acute‐remission plasma samples used in
SOMAscan screening by ELISA

F I G U R E 3 Responses of neutrophils from systemic capillary leak syndrome (SCLS) subjects to pro‐inflammatory mediators. Neutrophils
were isolated from whole blood and incubated left untreated (no treatment, NT) or treated with fMLP for 15 minutes in the presence
of cytochalasin B. (A), myeloperoxidase (MPO) released was measured by ELISA, and the data are expressed as the fold change in MPO
compared to unstimulated cells (mean ± SEM). (B‐D), Purified neutrophils were not treated (NT) or exposed to Lipopolysaccharide (LPS),
fMLP or TNFα for one hour. Cells were immunostained with antibodies against the indicated markers and surface expression analysed by
flow cytometry. Data are expressed as geometric mean florescence intensity (GMFI) (mean ± SEM); *P < 0.05, Mann‐Whitney u test

3.5 | Neutrophil degranulation and vascular
barrier integrity

healthy donors with medium alone or fMLP. We confirmed neutrophil
degranulation by MPO assay (Figure S3A). We then treated ECs with
supernatants from the activated neutrophils and measured transen‐

We tested the effects of neutrophil granule contents on endothe‐

dothelial electrical resistance (TER) across monolayers in real time.

lial barrier function. First, we stimulated neutrophils isolated from

fMLP‐stimulated neutrophil supernatants from two separate donors

XIE et al.
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nearly 2000% in acute plasma relative to matched convalescent
plasma. As early as 1977, tracking studies of proteins of varying mo‐
lecular weights in SCLS sera during flares determined that although
albumin (mw 62 kDa) levels decreased by 30%‐50% during an epi‐
sode, C1 (mw 200 KDa) decreased only 10% and IgM (mw 900 kDa)
levels rose in direct proportion to the increase in hematocrit.14 Thus,
proteins up to 900 kDa may extravasate during episodes of SCLS.
SOMA screening revealed that MPO (mw 150 kDa) levels increased
more than threefold in acute sera relative to baseline, whereas sev‐
eral unrelated proteins of similar size were not elevated in the same
samples (eg CHRDL [150 kDa], 1.01‐fold change in basal vs episodic
sera; NrCAM [140 kDa], −1.00‐fold; MET [145 kDa], 1.003‐fold). In
addition, SOMAScan underestimated the increases in MPO, as quan‐
titative ELISA revealed that absolute MPO levels actually increased
nearly 10‐fold in episodic vs remission plasma (Figure 2B). Thus, we
conclude that a) hemoconcentration alone could not account for ele‐
F I G U R E 4 Acute systemic capillary leak syndrome (SCLS)
sera elicit neutrophil activation. (A‐C), Purified neutrophils from
healthy donors were left untreated or incubated with acute or
remission SCLS sera for one hour followed by immunostaining with
antibodies against the indicated surface markers and analysis by
flow cytometry. Results are expressed as the fold change in the
percentage of cells positive for the indicated markers relative to
unstimulated cells; *P = 0.04, **P = 0.002, Mann‐Whitney u test

vations in circulating concentration of plasma proteins; b) changes in
plasma protein levels are not solely based extravasation due to size.
The impetus for neutrophil activation is still unknown. Because
many patients have infections preceding flares and most have ele‐
vated serum levels of pro‐inflammatory cytokines at the onset of an
attack, the factors inciting neutrophil activation may not be unique
to SCLS. Neutrophil degranulation occurs in other diseases associated
with systemic inflammation including sepsis. Notably, however, mean
plasma levels of azurophilic granule components such as MPO in acute
SCLS were nearly ninefold higher than those in septic plasma (514 vs

led to decreased TER (ie increased permeability) of HMVECs, while

60 ng/mL).15 Similarly, although elevated levels of tertiary granule con‐

the resistance of cells exposed to medium alone remained relatively

stituents including MMP9 are observed in sepsis and other systemic

constant over a period of 10 hours (Figure S3B). We next determined

diseases with prominent vascular abnormalities such as Kawasaki syn‐

the effects of degranulated neutrophil supernatants on ECs isolated

drome, levels of MMP9 are twofold to fivefold higher in SCLS.16

and expanded from peripheral blood of SCLS patients or healthy con‐

Our results thus far suggest that neutrophils from SCLS patients

trols BOECs.7 The activated neutrophil supernatants reduced TER

are not predisposed to degranulate or become activated in response

in a pattern similar to commercially supplied HMVECs (Figure 5A,B).

to routine inflammatory mediators. This was somewhat unexpected

However, the maximal decrease in resistance in BOECs from SCLS

since we discovered distinct transcriptomes and responses of SCLS

subjects and controls was equivalent at both early (30 minutes) and

ECs and peripheral blood mononuclear cells compared to healthy

later (15 hours) time points. Thus, although neutrophil granule con‐

controls.7,10 For example, monocytes and ECs from SCLS patients pro‐

stituents exert permeability‐inducing effects on ECs, our data do not

duced more pro‐inflammatory mediators—including adrenomedullin

suggest hypersensitivity of SCLS ECs to this stimulus.

(ADM) and CXCL10—in response to treatment with SCLS‐associated
cytokines (IFNγ) compared to controls.3,10 It is possible that SCLS

4 | D I S CU S S I O N

neutrophils may hyper‐respond to a constellation of SCLS‐associated
factors that cannot be fully recapitulated in vitro; limited sample avail‐
ability precludes us from formally testing this hypothesis at the present

From our proteomic screening study of SCLS plasma, we discovered

time through studies of matched patient neutrophils and acute sera.

that neutrophils are activated during SCLS disease flares. Neutrophil

Clinical manifestations of acute SCLS including hypovolemic

granule contents (primary, secondary and tertiary granules), in‐

shock and anasarca most likely result from disruption of the endo‐

cluding MPO, BPI, Cathepsin G, gelatinase and collagenases, were

thelial barrier of the soft tissue microvasculature. 2 The current study

increased in acute plasma relative to baseline, indicating systemic

suggests that neutrophil‐derived mediators contribute to endothe‐

neutrophil degranulation. Hemoconcentration and protein extrava‐

lial dysfunction in SCLS. MPO is a phagocytic peroxidase enzyme

sation are confounding factors for the interpretation of changes in

whose major product is hypochlorous acid, a potent microbicidal

levels of plasma proteins during an SCLS flare. The degree of hemo‐

agent, generated from hydrogen peroxide (H2O2), which plays a key

concentration in a typical SCLS episode is 50%‐80%, as indicated by

role in host responses.17 MPO and ROS including H2O2 have been

the mean change in hematocrit. In comparison, levels of (BPI, mw

shown to increase permeability of HMVEC monolayers in vitro.18

25 kDa), the top‐ranked protein from the SOMAScan screen, rose

In addition, MPO has the capacity to sequester nitric oxide (NO),

5126
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F I G U R E 5 Activated neutrophil supernatants enhance endothelial permeability. (A‐B), Transendothelial resistance (TER) across Blood
outgrowth endothelial cells from healthy subjects or systemic capillary leak syndrome (SCLS) patients was measured after application of
fMLP‐stimulated neutrophil supernatants for 30 minutes (A) or 15 hours (B). TER over time in a representative experiment is shown on the
left; bar graphs on right show the percentage decrease in baseline resistance at the indicated time points (mean ± SEM)

resulting in decreased bioavailability. NO promotes relaxation of
vascular smooth muscle and endothelial contraction and has been
implicated as a therapeutic target for SCLS‐associated hypoten‐
sion.19 Rodent studies show that MPO localizes at the vascular en‐
dothelium and extracellular matrix under inflammatory stress and
affects vascular smooth muscle and endothelial functions. 20 ROS
may also induce EC apoptosis; however, we did not observe apop‐
tosis of HMVECs incubated with acute or convalescent SCLS sera. 2
Another key finding is the increased activation of neutrophils
induced by acute but not basal sera, as indicated by the increased
percentage of the cells shedding CD62L. A CD16bright/CD62Ldim
neutrophil subset appears to be quite distinct from other neutrophil
subpopulations in vivo; published work has suggested that such cells
may be recruited from bone marrow to circulation in response to
acute inflammation.13 This subset is less adherent to ECs and may
F I G U R E 6 SOMAscan and other discovery‐driven approaches
to unraveling systemic capillary leak syndrome (SCLS) disease
mechanisms. Analysis of shared genes encoding proteins increased
greater than twofold in acute vs remission SCLS plasma and
transcripts significantly enriched >log2‐fold in SCLS Blood‐
outgrowth endothelial cells vs controls using GeneVenn. Shared
genes listed at bottom

play an immunosuppressive function as it preferentially migrates to
splenic white pulp and inhibits T cell proliferation.12,21 Whether this
neutrophil subpopulation has a distinct function in SCLS or simply
reflects de novo activation requires further study.
In summary, through multiplexed proteomic screening of plasma,
we have discerned a panoply of proteins enriched in plasma during
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SCLS flares that suggests widespread neutrophil activation/degranu‐
lation. Our results demonstrate the utility of SOMAscan as a discovery
tool for disease mechanisms. A comparison of genes encoding proteins
elevated in acute SCLS plasma with transcripts overexpressed SCLS
ECs compared to controls (unpublished RNA‐Seq data) revealed a pos‐
sible cellular source for several SCLS‐enriched proteins (Figure 6). As
but one example, platelet‐derived growth factor B, which is secreted
by ECs, stimulates proliferation and activation of pericytes, which are
smooth muscle‐like cells surrounding microvessels. Pericyte cover‐
age is required for maintenance of microvascular endothelial barrier
function in acute inflammation.22 We believe that these and other dis‐
covery‐driven approaches will eventually lead to advances in classifi‐
cation of SCLS and development of biomarkers for treatment efficacy.
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